Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
The first GLP-1 receptor agonist approved by the FDA, originally derived from Gila monster saliva. Available in twice-daily (Byetta) and once-weekly (Bydureon) formulations. Paved the way for semaglutide and tirzepatide.
A dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Represents the next generation of incretin-based therapies with potentially superior efficacy to semaglutide for weight loss.
Synthetic version of exendin-4, a peptide found in Gila monster venom that shares 53% homology with human GLP-1 but resists DPP-4 degradation. Stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety.
Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, producing enhanced insulin secretion, appetite suppression, and metabolic improvements beyond what single-agonist drugs achieve.
- Type 2 diabetes
- Blood sugar regulation
- Modest weight loss
- Weight management
- Type 2 diabetes treatment
- Metabolic health improvement
- Nausea (common, especially initially)
- Pancreatitis (rare)
- Injection site nodules (Bydureon)
- Renal impairment
- Thyroid C-cell tumors (animal studies)
- GI side effects (nausea, diarrhea, vomiting)
- Pancreatitis risk
- Injection site reactions
- Potential thyroid concerns
FDA-approved as Byetta (2005, twice daily) and Bydureon (2012, once weekly). The first-in-class GLP-1 agonist. Largely superseded by semaglutide for new prescriptions but still widely used.
FDA-approved as Mounjaro (diabetes, 2022) and Zepbound (weight management, 2023).
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.